Digest Network Come funziona
Network
/
Società
Ag
Non verificato

Agenus Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

90 comunicati stampa

Guarda tutti i comunicati
06/11/2026
Eventi
Industria
Igiene alimentare
Farmaceutica
Oncologia
Sanità
Terza età
Biotecnologia
Medicina - Varie
Scienza
Vetrine/Shopping
Assistenza all'Infanzia
Salute
Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
05/11/2026
Mercato azionario
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
02/11/2026
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Oncologia
Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
02/11/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
25/10/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
22/10/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Finanza
Mercato azionario
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
09/10/2026
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Oncologia
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
08/10/2026
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
03/10/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Eventi
Industria
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
02/10/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0